Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure

Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Zhuravleva, S. N. Tereshchenko, I. V. Zhirov, S. V. Villevalde, T. V. Marin, Yu. V. Gagarina
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2022-01-01
Series:	Российский кардиологический журнал
Subjects:	dapagliflozin heart failure with reduced ejection fraction target indicators mortality from circulatory system diseases state program “development of healthcare” federal project “fight against cardiovascular diseases”
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4800
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)

Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
by: M. V. Zhuravleva, et al.
Published: (2022-03-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2023-04-01)

Contribution of ticagrelor therapy in patients with acute coronary syndrome and patients with myocardial infarction to the achievement of State Program "Health Development" target in Russia as a whole and Russian regions in 2023-2025
by: M. V. Zhuravleva, et al.
Published: (2024-02-01)

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF
by: Andrew P. Ambrosy, et al.
Published: (2025-06-01)

Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2024-08-01)

Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates
by: M. V. Zhuravleva, et al.
Published: (2020-12-01)

Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension
by: M. V. Zhuravleva, et al.
Published: (2025-05-01)

Clinical and economic analysis of the use of the medicinal product dapagliflozin in patients with chronic heart failure and type 2 diabetes mellitus
by: M. V. Zhuravleva, et al.
Published: (2024-07-01)

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper
by: João Pedro Ferreira, et al.
Published: (2025-08-01)

Dynamics of chronic heart failure with a low ejection fraction when dapagliflozin is included in standard therapy
by: A. A. Tsareva, et al.
Published: (2024-04-01)

Las medidas de protección del informante: la base de la funcionalidad del sistema
by: Javier Eduardo Quesada Lumbreras
Published: (2024-04-01)

Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
by: Marwa M. Saeed
Published: (2024-12-01)

Effect of dapagliflozin in paroxysmal atrial fibrillation combined with heart failure with preserved ejection fraction: a randomized controlled trial
by: Xiaoyu LIAN, et al.
Published: (2025-06-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Dynamics of uric acid concentration against the background of early dapagliflozin use in patients with acute decompensation of heart failure
by: Laura H. Sarieva, et al.
Published: (2024-01-01)

Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region
by: A. D. Ermolaeva, et al.
Published: (2023-11-01)

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
by: Zh. D. Kobalava, et al.
Published: (2020-06-01)

Obesity paradox in chronic heart failure with moderately reduced or preserved left ventricular ejection fraction: impact on a prognosis for patients according to a five-year follow-up
by: P. P. Bidzilya, et al.
Published: (2023-07-01)

Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi‐Ethnic Study of Atherosclerosis: The Pooling Project
by: Sarah Nomura, et al.
Published: (2025-06-01)

The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
by: V. Yu. Perfil’ev, et al.
Published: (2017-04-01)

Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice
by: M. M. Loukianov, et al.
Published: (2020-03-01)

To a question of the factors influencing efficiency of criminal and legal fight against crimes, breaking copyright
by: A. V. Borisov
Published: (2020-01-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

DRESS syndrome with the use of dapagliflozin: A case report and review of literature
by: Rebecca Badawi, et al.
Published: (2025-07-01)

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2023-12-01)

Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction
by: Song‐Yun Chu, et al.
Published: (2025-02-01)

Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review
by: Lu Wang, et al.
Published: (2024-12-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)

Dynamics of heart failure markers and cardiac reverse remodeling in patients receiving cardiac contractility modulation therapy
by: M. A. Vander, et al.
Published: (2021-02-01)

The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats
by: Albanna AA, et al.
Published: (2025-07-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation
by: Atthaphong Phongphithakchai, et al.
Published: (2025-03-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

Effect of Noncardiac Comorbidities on Quality of Life among Patients with Heart Failure - An Observational Study
by: J. Anusha, et al.
Published: (2025-07-01)